Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

(2014) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Adominal Infections - The European Experience

(2014) P. Fomin et al.   JOURNAL OF CHEMOTHERAPY

Safety and Efficacy of Intravenous Doripenem for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis

(2014) R. Redman et al.   JOURNAL OF CHEMOTHERAPY

Clinical Outcomes of Enterobacteriaceae Infections Stratified by Carbapenem MICs

(2014) Twisha S. Patel et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The FDA Reboot of Antibiotic Development

(2013) David M. Shlaes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

(2013) George G. Zhanel et al.   DRUGS

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

Secular Trends in Gram-Negative Resistance among Urinary Tract Infection Hospitalizations in the United States, 2000–2009

(2013) Marya D. Zilberberg et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010

(2012) Dawn M. Sievert et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Efficacy of Tigecycline versus Ceftriaxone Plus Metronidazole for the Treatment of Complicated Intra-Abdominal Infections: Results from a Randomized, Controlled Trial

(2012) Niels Qvist et al.   Surgical Infections

Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections–Proceedings and Data From the Gram-Negative Resistance Summit

(2011) Marin H. Kollef et al.   CLINICAL INFECTIOUS DISEASES

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

(2011) Souha S. Kanj et al.   MAYO CLINIC PROCEEDINGS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease

(2010) Yun Cai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

(2010) Zhangjing Chen et al.   BMC INFECTIOUS DISEASES

Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis

(2009) K. G. Naber et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline

(2009) Matthew Falagas et al.   CURRENT DRUG METABOLISM

Choosing Antibiotics for Intra-Abdominal Infections: What Do We Mean by “High Risk”?

(2009) Brian R. Swenson et al.   Surgical Infections

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study

(2008) Christopher Lucasti et al.   CLINICAL THERAPEUTICS

Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

(2008) Johann DD Pitout et al.   LANCET INFECTIOUS DISEASES